D Massi1, D Brusa2, B Merelli3, M Ciano2, V Audrito4, S Serra4, R Buonincontri4, G Baroni1, R Nassini5, D Minocci5, L Cattaneo6, E Tamborini7, A Carobbio8, E Rulli9, S Deaglio4, M Mandalà10. 1. Department of Surgery and Translational Medicine, Division of Pathological Anatomy, University of Florence. 2. Human Genetics Foundation (HuGeF), Turin. 3. Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo. 4. Human Genetics Foundation (HuGeF), Turin Department of Medical Sciences, University of Turin , Turin. 5. Unit of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Firenze. 6. Division of Pathological Anatomy, Papa Giovanni XXIII Hospital, Bergamo. 7. Department of Pathology, Experimental Molecular Pathology, National Cancer Institute, Milan. 8. Research Foundation, Papa Giovanni XXIII Hospital, Bergamo. 9. Department of Oncology, Clinical Research Laboratory, Mario Negri Institute IRCCS, Milan, Italy. 10. Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo mariomandala@tin.it.
Abstract
BACKGROUND: Programmed cell death ligand 1 (PD-L1) is a cell surface molecule that plays a critical role in suppressing immune responses, mainly through binding of the PD-1 receptor on T lymphocytes. PD-L1 may be expressed by metastatic melanoma (MM). However, its clinical and biological significance remains unclear. Here, we investigated whether expression of PD-L1 in MM identifies a biologically more aggressive form of the disease, carrying prognostic relevance. PATIENTS AND METHODS: PD-L1 expression was analyzed by immunohistochemistry using two different antibodies in primary tumors and paired metastases from 81 melanoma patients treated at a single institution. Protein expression levels were correlated with PD-L1 mRNA, BRAF mutational status and clinical outcome. PD-L1(+) and PD-L1(-) subsets of the A375 cell line were stabilized in vitro and compared using gene expression profiling and functional assays. Results were confirmed using xenograft models. RESULTS: PD-L1 membrane positivity was detected in 30/81 (37%) of patients. By multivariate analysis, Breslow thickness and PD-L1 membrane positivity were independent risk factors for melanoma-specific death {PD-L1 5% cutoff [hazard ratio (HR) 3.92, confidence interval (CI) 95% 1.61-9.55 P < 0.003], PD-L1 as continuous variable (HR 1.03, 95% CI 1.02-1.04 P < 0.002)}. PD-L1 expression defined a subset of the BRAF-mutated A375 cell line characterized by a highly invasive phenotype and by enhanced ability to grow in xenograft models. CONCLUSIONS: PD-L1 is an independent prognostic marker in melanoma. If confirmed, our clinical and experimental data suggest that PD-L1(+) melanomas should be considered a disease subset with distinct genetic and morpho-phenotypic features, leading to enhanced aggressiveness and invasiveness.
BACKGROUND:Programmed cell death ligand 1 (PD-L1) is a cell surface molecule that plays a critical role in suppressing immune responses, mainly through binding of the PD-1 receptor on T lymphocytes. PD-L1 may be expressed by metastatic melanoma (MM). However, its clinical and biological significance remains unclear. Here, we investigated whether expression of PD-L1 in MM identifies a biologically more aggressive form of the disease, carrying prognostic relevance. PATIENTS AND METHODS: PD-L1 expression was analyzed by immunohistochemistry using two different antibodies in primary tumors and paired metastases from 81 melanomapatients treated at a single institution. Protein expression levels were correlated with PD-L1 mRNA, BRAF mutational status and clinical outcome. PD-L1(+) and PD-L1(-) subsets of the A375 cell line were stabilized in vitro and compared using gene expression profiling and functional assays. Results were confirmed using xenograft models. RESULTS:PD-L1 membrane positivity was detected in 30/81 (37%) of patients. By multivariate analysis, Breslow thickness and PD-L1 membrane positivity were independent risk factors for melanoma-specific death {PD-L1 5% cutoff [hazard ratio (HR) 3.92, confidence interval (CI) 95% 1.61-9.55 P < 0.003], PD-L1 as continuous variable (HR 1.03, 95% CI 1.02-1.04 P < 0.002)}. PD-L1 expression defined a subset of the BRAF-mutated A375 cell line characterized by a highly invasive phenotype and by enhanced ability to grow in xenograft models. CONCLUSIONS:PD-L1 is an independent prognostic marker in melanoma. If confirmed, our clinical and experimental data suggest that PD-L1(+) melanomas should be considered a disease subset with distinct genetic and morpho-phenotypic features, leading to enhanced aggressiveness and invasiveness.
Authors: Ha Linh Vu; Sheera Rosenbaum; Timothy J Purwin; Michael A Davies; Andrew E Aplin Journal: Pigment Cell Melanoma Res Date: 2015-09 Impact factor: 4.693
Authors: David M Woods; Rupal Ramakrishnan; Andressa S Laino; Anders Berglund; Kelly Walton; Brian C Betts; Jeffrey S Weber Journal: Clin Cancer Res Date: 2018-08-21 Impact factor: 12.531
Authors: Miguel Angel Martinez-Garcia; Francisco Campos-Rodriguez; Isaac Almendros; Francisco Garcia-Rio; Manuel Sanchez-de-la-Torre; Ramon Farre; David Gozal Journal: Am J Respir Crit Care Med Date: 2019-12-01 Impact factor: 21.405
Authors: Mi-Heon Lee; Jane Yanagawa; Linh Tran; Tonya C Walser; Bharti Bisht; Eileen Fung; Stacy J Park; Gang Zeng; Kostyantyn Krysan; William D Wallace; Manash K Paul; Luc Girard; Boning Gao; John D Minna; Steven M Dubinett; Jay M Lee Journal: Am J Transl Res Date: 2020-02-15 Impact factor: 4.060